XINT Stock Overview
A biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Xintela AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.35 |
| 52 Week High | SEK 0.65 |
| 52 Week Low | SEK 0.21 |
| Beta | 1.76 |
| 11 Month Change | -26.36% |
| 3 Month Change | -31.65% |
| 1 Year Change | 41.94% |
| 33 Year Change | -84.00% |
| 5 Year Change | -92.18% |
| Change since IPO | -91.56% |
Recent News & Updates
Shareholder Returns
| XINT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.5% | -5.8% | -2.1% |
| 1Y | 41.9% | 14.3% | 10.8% |
Return vs Industry: XINT exceeded the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: XINT exceeded the Swedish Market which returned 10.8% over the past year.
Price Volatility
| XINT volatility | |
|---|---|
| XINT Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: XINT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: XINT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Evy Lundgren-Åkerlund | www.xintela.se |
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Xintela AB (publ) Fundamentals Summary
| XINT fundamental statistics | |
|---|---|
| Market cap | SEK 200.20m |
| Earnings (TTM) | -SEK 40.83m |
| Revenue (TTM) | SEK 381.00k |
525.5x
P/S Ratio-4.9x
P/E RatioIs XINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XINT income statement (TTM) | |
|---|---|
| Revenue | SEK 381.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 381.00k |
| Other Expenses | SEK 41.21m |
| Earnings | -SEK 40.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 22, 2024
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 100.00% |
| Net Profit Margin | -10,715.75% |
| Debt/Equity Ratio | 0% |
How did XINT perform over the long term?
See historical performance and comparison